TScan Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 6, 2026
TCRX$0.19+2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Revenue: | ||
| Collaboration and license revenue | $982 | $2,171 |
| Operating expenses: | ||
| Research and development | 21,904 | 29,788 |
| General and administrative | 8,217 | 8,633 |
| Total operating expenses | 30,121 | 38,421 |
| Loss from operations | (29,139) | (36,250) |
| Other (expense) income: | ||
| Interest and other income, net | 1,162 | 2,802 |
| Interest expense | (689) | (679) |
| Total other income | 473 | 2,123 |
| Net loss | $(28,666) | $(34,127) |
| Net loss per share, basic and diluted | $(0.22) | $(0.26) |
| Weighted average common shares outstanding—basic and diluted | 129,913,376 | 129,678,572 |
| Comprehensive loss: | ||
| Net Loss | $(28,666) | $(34,127) |
| Other comprehensive loss: | ||
| Unrealized loss on available-for-sale securities | - | (55) |
| Comprehensive loss | $(28,666) | $(34,182) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.